Délimiter le marché de la santé et faire le droit du vivant. Le rôle des oppositions juridiques aux brevets sur les gènes en Europe

Maurice Cassier

Revue d'économie industrielle, 2007, vol. n° 120, issue 4, 9-9

Abstract: Procedures of legal opposition to patents in Europe are trials which delimit the extension of intellectual property and markets, and which shape the law. In biotechnology and health, the rate of opposition is traditionally higher, and the opponents more heterogeneous, than in other sectors of innovation. Instances of opposition to patents owned by the US company Myriad Genetics are legal precedents as regards life forms and health: they have led to the adoption of stricter criteria for examining patents on gene sequences and to amendments to intellectual property law, especially in France and Belgium. Total or partial revocation of patents on genes and breast cancer gene tests in Europe has limited the extension of private health-care markets and supported the hospital economy and the free use of these genes.

Keywords: Patent; Opposition Procedure; Genes; Health Market (search for similar items in EconPapers)
Date: 2007
References: Add references at CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
http://www.cairn.info/load_pdf.php?ID_ARTICLE=REI_120_0009 (application/pdf)
http://www.cairn.info/revue-d-economie-industrielle-2007-4-page-9.htm (text/html)
free

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:cai:reidbu:rei_120_0009

Access Statistics for this article

More articles in Revue d'économie industrielle from De Boeck Université
Bibliographic data for series maintained by Jean-Baptiste de Vathaire ().